title: A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease.
abstract: Sustained virologic response rates for hepatitis C virus are difficult to achieve in patients infected with human immunodeficiency virus, especially if they have other poor predictors of response. Rates of sustained virologic response for hepatitis C virus genotype 1 in patients with end stage kidney disease are lower than patients with normal renal function. We present the first case report of a co-infected African American man with end stage kidney disease, who was haemodialysis dependant, and an interferon non-responder with advanced liver fibrosis, who achieved sustained virologic response on a telaprevir-based regimen.
authors.affiliation: St. Michaels Medical Center, Infectious Diseases Department, Seton Hall University, Newark, NJ, USA jsmdsmmc@gmail.com.
authors.forename: J
authors.initials: J
authors.lastname: Slim
authors.affiliation: St. Michaels Medical Center, Infectious Diseases Department, Seton Hall University, Newark, NJ, USA.
authors.forename: N
authors.initials: N
authors.lastname: Scangarello
authors.affiliation: St. Michaels Medical Center, Infectious Diseases Department, Seton Hall University, Newark, NJ, USA.
authors.forename: P
authors.initials: P
authors.lastname: Samaha
authors.affiliation: St. Michaels Medical Center, Infectious Diseases Department, Seton Hall University, Newark, NJ, USA.
authors.forename: J
authors.initials: J
authors.lastname: Dazley
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C486464:telaprevir
keywords: HIV; end stage kidney disease; hepatitis C; telaprevir; treatment